Biomechanical models in the lower-limb exoskeletons development: a review.
Vahid Firouzi, Andre Seyfarth, Seungmoon Song and 2 others
PMID 39856714WHAT IT FOUND
Biomechanical models guide exoskeleton design by predicting metabolic savings and joint loads before human trials.
However, most simulations test healthy users, not patients, and lack experimental validation, so predicted benefits may not translate to clinical populations.
Key findings
01Most model-based exoskeleton designs prioritize reducing metabolic cost and muscle effort in healthy users, rather than addressing specific pathological gait needs.
02There is a significant gap between simulation and experimental validation, particularly for proximal joints like the hip, where many design advantages remain untested in humans.
03Assistive devices tested on healthy individuals do not guarantee the same metabolic or functional benefits for patients with pathological gait.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The review covers publications only up to June 2023. The search was limited to Google Scholar, which may miss some databases. The review highlights a lack of experimental validation for many simulated designs, particularly for hip assistance. Most reviewed studies focus on healthy subjects, limiting generalizability to clinical populations with pathological gait.
Declared interests
The study was supported by the Deutsche Forschungsgemeinschaft and Technische Universität Darmstadt. No commercial conflicts of interest were declared.
The easy way to misread this
Do not assume that exoskeletons designed using biomechanical models will provide the same metabolic or functional benefits to patients with pathological gait as they do to healthy users. The review explicitly states that improvements in healthy individuals do not guarantee effectiveness in clinical populations, and many designs lack experimental validation in patients.